The data of this pilot study suggest that perioperative subconjunctival decorin applications significantly affect conjunctival scarring and surgical outcome of glaucoma filtration treatments in rabbits.

The present study suggests that an intraocular application of 0.25 mg/ml bevacizumab for the treatment of CNV is reasonable. No significant short term effects of bevacizumab on retinal function were detected, but long term effects cannot be excluded.

Our results demonstrate the general feasibility of reproducible and reliable sutureless amniotic membrane fixation onto the corneal surface in rabbits. Stable adherence is maintained until epithelialization is completed. The sutureless technique gives sufficient manipulation time for the sheet before the final cross-linking process is completed. Furthermore, several advantageous characteristics could be demonstrated as increased biocompatibility, better epithelialization pattern and the lack of membrane shrinkage.

Aim: To investigate the retinal toxicity of bevacizumab in co-application with a commercially available recombinant tissue plasminogen activator (rt-PA), and to facilitate a new therapeutic concept in the treatment of massive subretinal haemorrhage caused by neovascular age-related macular degeneration (AMD). Methods: Isolated bovine retinas were perfused with an oxygen-preincubated nutrient solution. The electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes. Bevacizumab (0.25 mg/ml) and rt-PA (20 mg/ml) were added to the nutrient solution for 45 min. Thereafter, the retina was reperfused for 60 min with normal nutrient solution. Similarly, the effects of rt-PA (20 mg/ml, 60 mg/ml and 200 mg/ml) on the a-and b-wave amplitudes were investigated. The percentages of a-and b-wave reduction during application and at washout were calculated. Results: During application of bevacizumab (0.25 mg/ml) in co-application with 20 mg/ml (rt-PA), the ERG amplitudes remained stable. The concentrations of rt-PA alone (20 mg/ml and 60 mg/ml) did not induce significant reduction of the b-wave amplitude. In addition, 20 mg/ml rt-PA did not alter the a-wave amplitude. However, 60 mg/ml rt-PA caused a slight but significant reduction of the a-wave amplitude. A full recovery was detected for both concentrations during the washout. At the highest tested concentration of 200 mg/ml rt-PA, a significant reduction of the a-and b-wave amplitudes was provoked during the exposure. The reduction of ERG amplitudes remained irreversible during the washout. Conclusion: The present study suggests that a subretinal injection of 20 mg/ml rt-PA in co-application with bevacizumab (0.25 mg/ml) for the treatment of massive subretinal haemorrhage seems possible. This is a safety study. Therefore, we did not test the clinical effectiveness of this combined treatment.

Primary silicone oil stabilizes the retina during the critical period of active PVR and may limit the visual loss in selected high-risk eyes in the long term.

Characteristics of light-induced pupillary oscillations at constant light intensities have been investigated sparsely compared to sleepiness-related pupillary oscillations in darkness. This study presents the first controlled analysis of light-induced pupillary oscillations and their relationship to illumination. Pupillary oscillations of alert subjects were recorded by infrared video pupillography in different background lighting. Although showing obvious relationships of mean frequency and amplitude to light intensity, there were considerable inter- and intra-individual differences in the appearance of light-induced oscillations. As they looked rather similar to sleepiness waves, the question remains to identify light-induced oscillations in day light and to differentiate them from sleepiness-related oscillations.

No abstract

No abstract